What is olanzapine, including its pharmacology, indications, dosing, and adverse effects?

Olanzapine: A Second-Generation Antipsychotic Medication

Olanzapine is a second-generation (atypical) antipsychotic medication classified as a thienobenzodiazepine derivative that functions as a serotonin-dopamine receptor antagonist, primarily used to treat schizophrenia, bipolar disorder, and as an adjunct for chemotherapy-induced nausea and vomiting.

Pharmacology

Olanzapine exhibits pleotropic receptor binding with greater affinity for serotonin 5-HT2A receptors than dopamine D2 receptors, which distinguishes it from typical antipsychotics 1, 2. This receptor profile is similar to clozapine but without the risk of agranulocytosis 1. The drug also affects muscarinic and adrenergic systems 3.

Key pharmacokinetic properties:

• Well absorbed orally; food does not affect absorption 1
• Peak plasma levels reached in 5-8 hours 3
• Half-life approximately 35 hours 3
• Therapeutic blood concentration range: 20-40 ng/mL (12 hours post-dose) 4
• This concentration corresponds to optimal D2-receptor occupancy of 65-80% 4

Clinical Indications

Primary FDA-Approved Uses 5:

Schizophrenia (adults and adolescents ≥13 years):

• Effective against both positive and negative symptoms 2
• Superior to haloperidol for negative and depressive symptoms 2
• Comparable or superior efficacy to risperidone 2, 3

Bipolar I Disorder:

• Acute manic or mixed episodes (adults and adolescents ≥13 years) 5
• Maintenance therapy for relapse prevention 6
• Superior to placebo and equal/superior to valproate for acute mania 6
• More efficacious than placebo in preventing both manic and depressive relapses 6

Combination therapy with fluoxetine:

• Treatment-resistant depression
• Bipolar depression 6

Off-Label Uses Supported by Guidelines:

Delirium management (particularly in cancer patients) 7:

• Starting dose: 2.5-5 mg PO or SC stat
• Scheduled dosing: 2.5-5 mg daily (usually at bedtime) if needed
• Reduce dose in older patients and those with hepatic impairment
• Available as orally disintegrating tablet (ODT) and IM formulation

Chemotherapy-induced nausea and vomiting (CINV) 8:

• Category 1 recommendation for highly emetogenic chemotherapy (HEC) when combined with NK1 receptor antagonist, 5-HT3 antagonist, and dexamethasone 8
• Significantly superior to placebo: complete response rates of 64% vs 41% over 120 hours (p<0.001) 8
• Also effective for breakthrough emesis (Category 1 recommendation) 8
• Dose: typically 5-10 mg daily 9, 10

Agitation in dementia (Alzheimer's disease) 11:

• Initial dose: 2.5 mg daily at bedtime
• Maximum: 10 mg daily (usually divided twice daily)
• Generally well tolerated in this population 11

Dosing Guidelines

Schizophrenia:

• Starting dose: 5-10 mg orally once daily 5, 1
• Target range: 10-20 mg daily
• Maximum: 20 mg daily (though higher doses have been used) 3

Bipolar Disorder:

• Acute mania: Start 10-15 mg daily
• Maintenance: 5-20 mg daily

Special Populations:

• Elderly/frail patients: Start at 2.5 mg and titrate gradually 7
• Hepatic impairment: Reduce dose 7
• Renal impairment: No specific adjustment required (unlike risperidone) 2

Long-Acting Injectable (LAI) Formulation:

• Novel subcutaneous extended-release formulation (TV-44749) shows sustained release over monthly dosing intervals 12
• Reaches clinically relevant concentrations (≥10 ng/mL) within 1-2 days 12
• Bioavailability 95-112% compared to oral formulation 12

Adverse Effects

Most Common (≥5% and twice placebo rate) 5:

In adults with schizophrenia:

• Postural hypotension
• Constipation
• Weight gain
• Dizziness
• Akathisia

In adolescents:

• Sedation
• Weight gain
• Headache
• Increased appetite
• Abdominal pain

In bipolar disorder:

• Asthenia
• Dry mouth
• Somnolence
• Tremor

Metabolic Effects (Major Concern):

Weight gain is the most significant adverse effect 5, 2, 13:

• Approximately 40% of patients gain weight in clinical trials 3
• Greater weight gain compared to risperidone 2, 13
• Risk highest with high starting doses and in underweight patients 3
• Weight gain may occur even at therapeutic blood levels 4

Metabolic syndrome components 5:

• Hyperglycemia and diabetes mellitus (including ketoacidosis, hyperosmolar coma, or death in extreme cases)
• Dyslipidemia
• Requires fasting glucose and lipid monitoring at baseline and periodically during treatment 5

Cardiovascular Effects:

• Orthostatic hypotension (especially during initial titration) 5
• Associated with dizziness, tachycardia, bradycardia, and syncope
• Use caution in patients with cardiovascular or cerebrovascular disease 5
• Does NOT significantly prolong QTc interval (unlike some other antipsychotics) 2, 3

Neurological Effects:

• Significantly fewer extrapyramidal symptoms (EPS) than haloperidol and risperidone 2
• Lower risk of tardive dyskinesia compared to typical antipsychotics 1
• Seizure risk: use cautiously in patients with seizure history 5
• Potential for cognitive and motor impairment 5

Hematologic:

• Leukopenia, neutropenia, and agranulocytosis reported (though NOT at clozapine-level risk) 5
• Monitor CBC in patients with history of low WBC 5

Endocrine:

• Hyperprolactinemia (but less than risperidone) 2, 13
• Less sexual dysfunction compared to other antipsychotics 3

Hepatic:

• Transient, asymptomatic elevations in liver enzymes 1, 13
• Monitor liver function tests 5

Anticholinergic Effects:

• Dry mouth
• Constipation (dose-dependent) 1
• Use caution with other anticholinergic drugs and in patients with urinary retention, prostatic hypertrophy, or paralytic ileus 5

Rare but Serious:

• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Discontinue immediately if suspected 5
• Neuroleptic Malignant Syndrome: Manage with immediate discontinuation 5

Critical Drug Interactions and Warnings

Dangerous Combinations:

Benzodiazepines 7:

• CRITICAL WARNING: Fatalities reported with concurrent use of benzodiazepines with high-dose olanzapine
• Risk of oversedation and respiratory depression
• If combination necessary, use lowest effective doses and monitor closely

Other CNS depressants:

• Alcohol: may potentiate orthostatic hypotension 5
• Diazepam: may potentiate orthostatic hypotension 5
• Lorazepam (IM): increased somnolence with IM olanzapine 5

Medications Affecting Olanzapine Levels:

Carbamazepine: Increases olanzapine clearance (may require dose adjustment) 5

Fluvoxamine: May increase olanzapine levels 5

Avoid Excessive Dopamine Blockade:

• Use caution when combining with metoclopramide, phenothiazines, or haloperidol 8

Other Interactions:

• Antihypertensive agents: enhanced antihypertensive effect 5
• Levodopa/dopamine agonists: olanzapine may antagonize their effects 5

Monitoring Requirements 14, 5

Before Starting Treatment:

• BMI and waist circumference
• Blood pressure
• HbA1c or fasting glucose
• Fasting lipid profile
• Prolactin level
• Liver function tests
• Urea and electrolytes
• Complete blood count
• Electrocardiogram

During Treatment:

• Weeks 1-6: BMI, waist circumference, and blood pressure weekly
• Week 4: Fasting glucose (or random if fasting not possible)
• Month 3: Repeat all baseline measures
• Annually thereafter: Repeat all baseline measures

Special Populations and Precautions

Elderly Patients:

• BLACK BOX WARNING: Increased mortality in elderly patients with dementia-related psychosis 5
• Start with lower doses (2.5 mg) and titrate gradually 7, 11
• Consider 5 mg dose in oversedated elderly patients 8

Pregnancy:

• May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure 5

Pediatric Use:

• Safety and effectiveness in children <13 years not established for schizophrenia/bipolar disorder 5
• Safety and effectiveness in children <10 years not established for olanzapine-fluoxetine combination 5

Suicide Risk:

• Close supervision required in high-risk patients with schizophrenia or bipolar disorder 5

Clinical Advantages Over Other Antipsychotics

Compared to haloperidol 2:

• Superior efficacy for negative and depressive symptoms
• Comparable efficacy for positive symptoms
• Significantly fewer extrapyramidal symptoms
• Lower 1-year relapse/rehospitalization risk
• No QTc prolongation

Compared to risperidone 2:

• Superior for negative and depressive symptoms (in some studies)
• Significantly fewer extrapyramidal symptoms
• Less hyperprolactinemia
• Less sexual dysfunction
• Greater weight gain (disadvantage)

Compared to clozapine 1, 2:

• No risk of agranulocytosis
• No mandatory blood monitoring
• Similar receptor affinity profile

Cost-Effectiveness

Despite higher acquisition costs compared to typical antipsychotics, olanzapine may reduce overall treatment costs through:

• Decreased hospitalization rates 2
• Reduced outpatient service utilization 2
• Improved quality of life 2
• Better treatment adherence due to favorable side effect profile

Common Clinical Pitfalls

1. Underestimating metabolic risk: Weight gain and metabolic syndrome can occur even at therapeutic doses—proactive monitoring and lifestyle interventions are essential

2. Combining with benzodiazepines without caution: This combination has caused fatalities; use only when absolutely necessary with close monitoring

3. Inadequate dose reduction in elderly/hepatic impairment: Always start low (2.5 mg) and titrate slowly in these populations

4. Ignoring early weight gain: Address weight gain immediately with dietary counseling and consider dose adjustment or switch if significant

5. Forgetting baseline and ongoing metabolic monitoring: This is not optional—metabolic complications are a major cause of morbidity

6. Using in dementia without considering black box warning: Weigh risks carefully; only use when benefits clearly outweigh mortality risk

7. Overlooking drug interactions: Particularly with CYP450 inducers/inhibitors and CNS depressants